Home > Haematology > ASH 2020 > Lymphoma > Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL

Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL

Presented By
Dr Caron Jacobson, Dana Farber Cancer Institute, Massachusetts, USA
Conference
ASH 2020
Trial
Phase 2, ZUMA-5
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimaeric antigen receptor (CAR) T cell therapy approved for the treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy, demonstrated considerable and durable clinical benefit in patients with R/R indolent non-Hodgkin lymphoma (iNHL) [1]. Axi-cel had a manageable safety profile, with lower rates of grade ≥3 neurologic events observed in patients with follicular lymphoma compared with patients with marginal zone lymphoma and with aggressive NHL [2]. Patients with advanced-stage iNHL, including follicular lymphoma and marginal zone lymphoma, frequently relapse with standard treatment. Axi-cel had positive results in relapsed LBCL [3] and is therefore investigated as potential therapy in iNHL. Dr Caron Jacobson (Dana Farber Cancer Institute, Massachusetts, USA) presented the primary analysis of ZUMA-5 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on